Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1948 1
1950 1
1956 1
1961 1
1962 1
1966 1
1969 1
1972 1
1973 1
1976 1
1978 1
1984 2
1985 1
1986 1
1988 1
1989 1
1990 1
1991 5
1992 3
1993 1
1994 1
1995 4
1997 1
1999 1
2008 1
2011 2
2012 1
2013 9
2014 3
2015 5
2016 5
2017 4
2018 2
2019 5
2020 5
2021 7
2022 2
2023 2
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

83 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
Mehanna H, Robinson M, Hartley A, Kong A, Foran B, Fulton-Lieuw T, Dalby M, Mistry P, Sen M, O'Toole L, Al Booz H, Dyker K, Moleron R, Whitaker S, Brennan S, Cook A, Griffin M, Aynsley E, Rolles M, De Winton E, Chan A, Srinivasan D, Nixon I, Grumett J, Leemans CR, Buter J, Henderson J, Harrington K, McConkey C, Gray A, Dunn J; De-ESCALaTE HPV Trial Group. Mehanna H, et al. Lancet. 2019 Jan 5;393(10166):51-60. doi: 10.1016/S0140-6736(18)32752-1. Epub 2018 Nov 15. Lancet. 2019. PMID: 30449623 Free PMC article. Clinical Trial.
Dysphagia-optimised intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in patients with head and neck cancer (DARS): a phase 3, multicentre, randomised, controlled trial.
Nutting C, Finneran L, Roe J, Sydenham MA, Beasley M, Bhide S, Boon C, Cook A, De Winton E, Emson M, Foran B, Frogley R, Petkar I, Pettit L, Rooney K, Roques T, Srinivasan D, Tyler J, Hall E; DARS Trialist Group. Nutting C, et al. Among authors: pettit l. Lancet Oncol. 2023 Aug;24(8):868-880. doi: 10.1016/S1470-2045(23)00265-6. Epub 2023 Jul 6. Lancet Oncol. 2023. PMID: 37423227 Free article. Clinical Trial.
Coronavirus Disease 2019: the Pivotal Role of UK Clinical Oncology and the UK Coronavirus Cancer Monitoring Project.
Best J, Starkey T, Chatterjee A, Fackrell D, Pettit L, Srihari N, Tween H, Olsson-Brown A, Cheng V, Hughes DJ, Lee AJX, Purshouse K, Arnold R, Uk Coronavirus Cancer Monitoring Project Team, Sivakumar S, Cazier JB, Lee LYW. Best J, et al. Among authors: pettit l. Clin Oncol (R Coll Radiol). 2021 Jan;33(1):e50-e53. doi: 10.1016/j.clon.2020.05.021. Epub 2020 Jun 5. Clin Oncol (R Coll Radiol). 2021. PMID: 32593552 Free PMC article. No abstract available.
Hormone Therapy for Breast Cancer in Men.
Khan MH, Allerton R, Pettit L. Khan MH, et al. Among authors: pettit l. Clin Breast Cancer. 2015 Aug;15(4):245-50. doi: 10.1016/j.clbc.2015.01.007. Epub 2015 Feb 7. Clin Breast Cancer. 2015. PMID: 26165199 Review.
Neuropsychological impairments in children with KCNJ11 neonatal diabetes.
Bowman P, Hattersley AT, Knight BA, Broadbridge E, Pettit L, Reville M, Flanagan SE, Shepherd MH, Ford TJ, Tonks J. Bowman P, et al. Among authors: pettit l. Diabet Med. 2017 Aug;34(8):1171-1173. doi: 10.1111/dme.13375. Diabet Med. 2017. PMID: 28477417 No abstract available.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. Earl HM, et al. Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178152 Free PMC article. Clinical Trial.
83 results